| HOME >> BIOLOGY >> TECHNOLOGY |
THRESHOLD PHARMACEUTICALS, INC.
(A Development Stage Enterprise)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(Unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
2007 2006 2007 2006
Revenue $359 $359 $1,077 $1,077
Operating expenses
Research and development 4,896 13,990 18,230 38,491
General and administrative 2,407 3,936 7,517 11,512
Total Operating Expenses 7,303 17,926 25,747 50,003
Loss from operations (6,944) (17,567) (24,670) (48,926)
Interest and other income 415 907 1,524 2,972
Interest expense (30) (53) (110) (112)
Net Loss $(6,559) $(16,713) $(23,256) $(46,066)
Net loss per basic and diluted
loss per common share $(0.18) $(0.46) $(0.63) $(1.27)
Weighted-average shares used in
computing basic and diluted
loss per common share 37,079 36,502 36,992 36,181
THRESHOLD PHARMACEUTICALS, INC.
(A Development Stage Enterprise)
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands)
September 30, December 31,
2007 2006
'/>"/>
| SOURCE Threshold Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |